These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27667740)

  • 1. Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.
    Gibbs JP; Slatter JG; Egbuna O; Geller M; Hamilton L; Dias CS; Xu RY; Johnson J; Wasserman SM; Emery MG
    J Clin Pharmacol; 2017 Apr; 57(4):513-523. PubMed ID: 27667740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
    Lee E; Gibbs JP; Emery MG; Block G; Wasserman SM; Hamilton L; Kasichayanula S; Hanafin P; Somaratne R; Egbuna O
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):281-289. PubMed ID: 30676701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.
    Kasichayanula S; Grover A; Emery MG; Gibbs MA; Somaratne R; Wasserman SM; Gibbs JP
    Clin Pharmacokinet; 2018 Jul; 57(7):769-779. PubMed ID: 29353350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
    Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
    Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
    J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
    Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Langslet G; Bays H; Blom D; Eriksson M; Dent R; Wasserman SM; Huang F; Xue A; Albizem M; Scott R; Stein EA
    J Am Coll Cardiol; 2014 Apr; 63(13):1278-1288. PubMed ID: 24509273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
    Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS;
    Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
    Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
    J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety evaluation of evolocumab.
    Roth EM
    Expert Opin Drug Saf; 2018 Jan; 17(1):99-106. PubMed ID: 28988500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
    Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.